Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).

This phase II study determined the efficacy and safety of alemtuzumab, a humanized anti-CD52 monoclonal antibody, delivered subcutaneously as first-line therapy, over a prolonged treatment period of 18 weeks in 41 patients with symptomatic B-cell chronic lymphocytic leukemia (B-CLL). Injections were...

Podrobná bibliografie
Hlavní autoři:	Lundin, J, Kimby, E, Björkholm, M, Broliden, P, Celsing, F, Hjalmar, V, Möllgård, L, Rebello, P, Hale, G, Waldmann, H, Mellstedt, H, Osterborg, A
Médium:	Journal article
Jazyk:	English
Vydáno:	2002

Podobné jednotky

Phase II study of subcutaneous alemtuzumab (Campath-1H) therapy of patients with previously untreated chronic lymphocytic leukemia (CLL).
Autor: Lundin, J, a další
Vydáno: (2001)

Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration.
Autor: Hale, G, a další
Vydáno: (2004)

The CAMPATH-1 antigen (CDw52).
Autor: Hale, G, a další
Vydáno: (1990)

Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
Autor: Hale, G, a další
Vydáno: (2002)

In vivo 'purging' of residual disease in CLL with Campath-1H.
Autor: Dyer, M, a další
Vydáno: (1997)

Alemtuzumab (CAMPATH-1H) for the treatment of acute rejection in kidney transplant recipients: long-term follow-up.
Autor: Clatworthy, MR, a další
Vydáno: (2009)

Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation: where do we go from here?
Autor: Chakrabarti, S, a další
Vydáno: (2004)

Campath 1H (alemtuzumab) in renal transplantation: 5-year comparative follow up.
Autor: Watson, C, a další
Vydáno: (2004)

Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen.
Autor: Xia, M, a další
Vydáno: (1993)

Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years.
Autor: Watson, C, a další
Vydáno: (2005)

CAMPATH: from concept to clinic.
Autor: Waldmann, H, a další
Vydáno: (2005)

Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL)
Autor: Marco Montillo, a další
Vydáno: (2008-03-01)

The evolving role of alemtuzumab (Campath-1H) in renal transplantation
Autor: Phuong-Thu T Pham, a další
Vydáno: (2008-12-01)

Impact on T-cell depletion and CD34+ cell recovery using humanised CD52 monoclonal antibody (CAMPATH-1H) in BM and PSBC collections; comparison with CAMPATH-1M and CAMPATH-1G.
Autor: Williams, R, a další
Vydáno: (2000)

Crystal structures of a rat anti-CD52 (CAMPATH-1) therapeutic antibody Fab fragment and its humanized counterpart.
Autor: Cheetham, G, a další
Vydáno: (1998)

Specificity of monoclonal antibody Campath-1.
Autor: Hale, G, a další
Vydáno: (1988)

Peripheral blood dendritic cells express CD52 and are depleted in-vivo by treatment with CAMPATH-1H.
Autor: Buggins, A, a další
Vydáno: (2001)

Availability of Campath-1 antibodies for bone marrow transplantation.
Autor: Hale, G, a další
Vydáno: (1995)

CAMPATH-1 monoclonal antibodies in bone marrow transplantation.
Autor: Hale, G, a další
Vydáno: (1994)

Characterization of the CAMPATH-1 (CDw52) antigen: biochemical analysis and cDNA cloning reveal an unusually small peptide backbone.
Autor: Xia, M, a další
Vydáno: (1991)

Alemtuzumab (Campath-1H) para tratamento da leucemia linfóide crônica
Autor: Maria Kadma da Silva Carriço, a další
Vydáno: (2003-06-01)

CAMPATH-1H in inflammatory arthritis.
Autor: Watts, R, a další
Vydáno: (1993)

T cell depletion with CAMPATH-1 in allogeneic bone marrow transplantation.
Autor: Hale, G, a další
Vydáno: (1988)

Anti-globulin responses to rat and humanized CAMPATH-1 monoclonal antibody used to treat transplant rejection.
Autor: Rebello, P, a další
Vydáno: (1999)

Recent results using CAMPATH-1 antibodies to control GVHD and graft rejection.
Autor: Hale, G, a další
Vydáno: (1996)

Reversal of allograft rejection using the monoclonal antibody, Campath-1G.
Autor: Friend, P, a další
Vydáno: (1991)

Leukaemic relapse after Campath 1-treated bone-marrow transplantation for leukaemia.
Autor: Waldmann, H, a další
Vydáno: (1987)

CAMPATH-1 MOAB IN THE TREATMENT OF REFRACTORY AUTOIMMUNE THROMBOCYTOPENIC PURPURA (ATP)
Autor: Lim, S, a další
Vydáno: (1993)

Campath-1 Abs 'in the bag' for hematological malignancies: the Cape Town experience.
Autor: Novitzky, N, a další
Vydáno: (2004)

CAMPATH-IH in multiple sclerosis.
Autor: Moreau, T, a další
Vydáno: (1996)

CAMPATH-1 antibodies in stem-cell transplantation.
Autor: Hale, G, a další
Vydáno: (2001)

CD52-Negative NK cells are abundant in the liver and less susceptible to alemtuzumab treatment
Autor: Hotta, R, a další
Vydáno: (2016)

Rat monoclonal antibodies for bone marrow transplantation--the CAMPATH series.
Autor: Waldmann, H, a další
Vydáno: (1985)

A personal history of the CAMPATH-1H antibody.
Autor: Waldmann, H
Vydáno: (2002)

EFFECTS OF MONOCLONAL-ANTIBODIES OF THE CAMPATH SERIES INVIVO - REQUIREMENTS FOR EFFECTIVE ANTIBODY THERAPY
Autor: Dyer, M, a další
Vydáno: (1988)

CAMPATH-1 monoclonal antibody therapy in severe refractory autoimmune thrombocytopenic purpura.
Autor: Lim, S, a další
Vydáno: (1993)

ISOTYPE VARIANTS OF CAMPATH-1 ANTIBODY - REQUIREMENTS FOR EFFECTIVE ANTIBODY ACTION INVIVO
Autor: Dyer, M, a další
Vydáno: (1989)

RAT MONOCLONAL-ANTIBODIES FOR BONE-MARROW TRANSPLANTATION (BMT) - THE CAMPATH SERIES
Autor: Waldmann, H, a další
Vydáno: (1985)

TREATMENT OF RHEUMATOID-ARTHRITIS WITH HUMANIZED ANTILYMPHOCYTE ANTIBODY CAMPATH-1H
Autor: Watts, R, a další
Vydáno: (1992)

Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. CAMPATH Users.
Autor: Hale, G, a další
Vydáno: (1998)